Insmed earnings missed by $0.07, revenue topped estimates
Insmed (INSM) reported Q3 EPS of -$0.46, missing estimates by $0.07, but revenue of $524.42M exceeded expectations. The stock is down 1.64% over 3 months and 50.07% over 12 months. Analysts have revised EPS 12 times positively and 2 times negatively in the last 90 days. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
The EPS miss may trigger sell pressure, while the revenue beat offers a modest positive note.
Market read
First‑time earnings release with a mixed beat/miss, relevant for biotech traders.
What to watch
Guidance outlook and pipeline updates were not disclosed, leaving upside potential uncertain.
Background
Insmed (NASDAQ: INSM) is a biotech firm focused on rare pulmonary diseases. The report covers its third‑quarter financial results.
Ticker impact
Insmed reported Q3 EPS of -$0.46, missing estimates by $0.07 and revenue of $524.42M beating the $497.11M consensus.
likely downside as market prices in the EPS miss
The EPS shortfall is a fresh, material data point that can move the share price in the near term.
Market effects
Biotech earnings miss may weigh on peer valuations.
U.S. biotech sector could see modest pullback.
Limited to investors tracking biotech earnings.
Counterpoint
Revenue beat could support a short‑term bounce if investors focus on top‑line growth.
Key entities
- companyInsmed
Biopharmaceutical company reporting Q3 results.



